Matti Annala - Concepedia

Author

Matti Annala

Also Known As

Annala, M, Annala, Matti, Gunilla Högnäs, M Annala, M J Annala, M. Annala, M.J. Annala, Matti Annala, Matti J. Annala, Stuart, Joshua

441

Publications

16.5K

Citations

H-Index

Concepts

All Affiliations

Tampere University University of British Columbia Tampere University Hospital BC Cancer Agency

About

Matti Annala is an author at Tampere University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	30	6.4K
2	Health Sciences	7	7	726
3	Engineering	1	1	41
4	Natural Sciences	1	1	47
5	Biostatistics	1	1	47

Matti Annala

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
The Molecular Taxonomy of Primary Prostate Cancer Adam Abeshouse, Jaeil Ahn, Rehan Akbani, Cell UrologyGenitourinary CancerMedicinePathologyPrimary Prostate Cancer	2015	3.1K
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Cancer Discovery PathologyRapid ResistanceInvasive BiomarkersTumor BiologyGenitourinary Cancer	2018	507
Integrated genomic characterization of endometrial carcinoma Gad Getz, Stacey Gabriel, Kristian Cibulskis, Carolina Digital Repository (University of North Carolina at Chapel Hill)	2013	414
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer Alexander W. Wyatt, Matti Annala, Rahul Aggarwal, JNCI Journal of the National Cancer Institute	2017	405
Evaluation of methods for modeling transcription factor sequence specificity Matthew T. Weirauch, Atina G. Coté, Raquel Norel, Nature Biotechnology Sequence MotifFunctional GenomicsGene Sequence AnnotationGene RecognitionGenetics	2013	401
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer Alexander W. Wyatt, Arun Azad, Stanislav Volik, JAMA Oncology	2016	378
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Daniel Khalaf, Matti Annala, Sinja Taavitsainen, The Lancet Oncology UrologyOncologyOptimal SequencingCrossover TrialGenitourinary Cancer	2019	338
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors David A. Quigley, Joshi J. Alumkal, Alexander W. Wyatt, Cancer Discovery	2017	259
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer Matti Annala, Werner J. Struss, Evan W. Warner, European Urology Genome InstabilityUrologyTumor LossMedicineGenetics	2017	216
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding Qilai Huang, Thomas Whitington, Ping Gao, Nature Genetics ChromatinMedicineIncreases Rfx6 ExpressionHoxb13 Chromatin BindingProstatic Disease	2014	215

Page 1